06.14.25 -- Outsourced Pharma Best Of May

Lynn Cinelli, VP Global Biologics Supply Chain, Bristol Myers Squibb, is fighting against sponsors who don’t recognize inefficiencies and flawed thinking fall hard on their external partners.

We need a flexible hiring marketplace – a new ecosystem – to generate increased awareness by professionals and students of positions in the biopharma industry. 

The total value of U.S. licensing of innovator drug candidates from Chinese biopharma companies has surged since 2020. How this R&D trend and those tariffs play out will impact your U.S.-based CDMOs.

How does a sponsor accurately transfer detailed knowledge about its product composition, development, and current manufacturing processes to its CDMO?

This session is designed to provide practical solutions for enhancing bioavailability and scalability in pharmaceutical formulations.

To safeguard the consistent delivery of essential therapies to patients around the world, biopharmaceutical companies, alongside their CDMO partners, are rethinking traditional supply models.